NCT04444141View on ClinicalTrials.gov

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Peripheral T-cell Lymphoma
Interventions
BIOLOGICAL

AK104

The subjects will receive AK104 till disease progression or for a maximum of 24 months.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Akeso

INDUSTRY